These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 31488229)

  • 1. Why do health technology assessment drug reimbursement recommendations differ between countries? A parallel convergent mixed methods study.
    Nicod E; Maynou L; Visintin E; Cairns J
    Health Econ Policy Law; 2020 Jul; 15(3):386-402. PubMed ID: 31488229
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Health Technology Assessment (HTA) Case Studies: Factors Influencing Divergent HTA Reimbursement Recommendations in Australia, Canada, England, and Scotland.
    Allen N; Walker SR; Liberti L; Salek S
    Value Health; 2017 Mar; 20(3):320-328. PubMed ID: 28292476
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Why do health technology assessment coverage recommendations for the same drugs differ across settings? Applying a mixed methods framework to systematically compare orphan drug decisions in four European countries.
    Nicod E
    Eur J Health Econ; 2017 Jul; 18(6):715-730. PubMed ID: 27538758
    [TBL] [Abstract][Full Text] [Related]  

  • 4. What is driving HTA decision-making? Evidence from cancer drug reimbursement decisions from 6 European countries.
    Maynou L; Cairns J
    Health Policy; 2019 Feb; 123(2):130-139. PubMed ID: 30477736
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Paradigms in operation: explaining pharmaceutical benefit assessment outcomes in England and Germany.
    Kieslich K
    Health Econ Policy Law; 2020 Jul; 15(3):370-385. PubMed ID: 30975237
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Towards Integrated Health Technology Assessment for Improving Decision Making in Selected Countries.
    Oortwijn W; Determann D; Schiffers K; Tan SS; van der Tuin J
    Value Health; 2017 Sep; 20(8):1121-1130. PubMed ID: 28964444
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of health technology assessment on pharmaceutical reimbursement in selected middle-income countries.
    Oortwijn W; Mathijssen J; Banta D
    Health Policy; 2010 May; 95(2-3):174-84. PubMed ID: 20074829
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Commonalities and differences in HTA outcomes: a comparative analysis of five countries and implications for coverage decisions.
    Nicod E; Kanavos P
    Health Policy; 2012 Dec; 108(2-3):167-77. PubMed ID: 23088802
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HTA programme response to the challenges of dealing with orphan medicinal products: Process evaluation in selected European countries.
    Nicod E; Annemans L; Bucsics A; Lee A; Upadhyaya S; Facey K
    Health Policy; 2019 Feb; 123(2):140-151. PubMed ID: 28400128
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Variation in Health Technology Assessment and Reimbursement Processes in Europe.
    Akehurst RL; Abadie E; Renaudin N; Sarkozy F
    Value Health; 2017 Jan; 20(1):67-76. PubMed ID: 28212972
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Developing an evidence-based methodological framework to systematically compare HTA coverage decisions: A mixed methods study.
    Nicod E; Kanavos P
    Health Policy; 2016 Jan; 120(1):35-45. PubMed ID: 26723201
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differences in Health Technology Assessment Recommendations Among European Jurisdictions: The Role of Practice Variations.
    Vreman RA; Mantel-Teeuwisse AK; Hövels AM; Leufkens HGM; Goettsch WG
    Value Health; 2020 Jan; 23(1):10-16. PubMed ID: 31952664
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparing Use of Health Technology Assessment in Pharmaceutical Policy among Earlier and More Recent Adopters in the European Union.
    Beletsi A; Koutrafouri V; Karampli E; Pavi E
    Value Health Reg Issues; 2018 Sep; 16():81-91. PubMed ID: 30316029
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Associations between uncertainties identified by the European Medicines Agency and national decision making on reimbursement by HTA agencies.
    Bloem LT; Vreman RA; Peeters NWL; Hoekman J; van der Elst ME; Leufkens HGM; Klungel OH; Goettsch WG; Mantel-Teeuwisse AK
    Clin Transl Sci; 2021 Jul; 14(4):1566-1577. PubMed ID: 33786991
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Threats to the value of Health Technology Assessment: Qualitative evidence from Canada and Poland.
    Wranik WD; Zielińska DA; Gambold L; Sevgur S
    Health Policy; 2019 Feb; 123(2):191-202. PubMed ID: 30554792
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of new medicines in Spain and comparison with other European countries.
    Epstein D; Espín J
    Gac Sanit; 2020; 34(2):133-140. PubMed ID: 31027840
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dealing with Uncertainty and Accounting for Social Value Judgments in Assessments of Orphan Drugs: Evidence from Four European Countries.
    Nicod E; Berg Brigham K; Durand-Zaleski I; Kanavos P
    Value Health; 2017; 20(7):919-926. PubMed ID: 28712621
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reimbursement of biosimilars in Poland: is there a link to health technology assessment?
    Neumann D; Jabłecka A
    Expert Rev Pharmacoecon Outcomes Res; 2016 Dec; 16(6):781-792. PubMed ID: 26768654
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HTA and decision-making processes in Central, Eastern and South Eastern Europe: Results from a survey.
    García-Mochón L; Espín Balbino J; Olry de Labry Lima A; Caro Martinez A; Martin Ruiz E; Pérez Velasco R
    Health Policy; 2019 Feb; 123(2):182-190. PubMed ID: 28420539
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Methods, procedures, and contextual characteristics of health technology assessment and health policy decision making: comparison of health technology assessment agencies in Germany, United Kingdom, France, and Sweden.
    Schwarzer R; Siebert U
    Int J Technol Assess Health Care; 2009 Jul; 25(3):305-14. PubMed ID: 19619349
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.